Exhibit 99.1 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in Glaucoma Expected in Q2 2024 Cash Expected to Support Operations Into At Least 2028 Based on $196M YE 2023 Cash Balance Plus$325M Gross Proceeds from February 2024 PIPE Planning to Host an Investor Day in Q2 2024 to ...